673 related articles for article (PubMed ID: 33552069)
21. Systems Immunology Analysis Reveals the Contribution of Pulmonary and Extrapulmonary Tissues to the Immunopathogenesis of Severe COVID-19 Patients.
Hammoudeh SM; Hammoudeh AM; Bhamidimarri PM; Al Safar H; Mahboub B; Künstner A; Busch H; Halwani R; Hamid Q; Rahmani M; Hamoudi R
Front Immunol; 2021; 12():595150. PubMed ID: 34262555
[TBL] [Abstract][Full Text] [Related]
22. Functional Reciprocity of Amyloids and Antimicrobial Peptides: Rethinking the Role of Supramolecular Assembly in Host Defense, Immune Activation, and Inflammation.
Lee EY; Srinivasan Y; de Anda J; Nicastro LK; Tükel Ç; Wong GCL
Front Immunol; 2020; 11():1629. PubMed ID: 32849553
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.
Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699
[TBL] [Abstract][Full Text] [Related]
24. The Many Faces of JAKs and STATs Within the COVID-19 Storm.
Grant AH; Estrada A; Ayala-Marin YM; Alvidrez-Camacho AY; Rodriguez G; Robles-Escajeda E; Cadena-Medina DA; Rodriguez AC; Kirken RA
Front Immunol; 2021; 12():690477. PubMed ID: 34326843
[TBL] [Abstract][Full Text] [Related]
25. Could Perturbation of Gut Microbiota Possibly Exacerbate the Severity of COVID-19
Vignesh R; Swathirajan CR; Tun ZH; Rameshkumar MR; Solomon SS; Balakrishnan P
Front Immunol; 2020; 11():607734. PubMed ID: 33569053
[No Abstract] [Full Text] [Related]
26. COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel.
Napodano C; Pocino K; Stefanile A; Marino M; Miele L; Gulli F; Basile V; Pandolfi F; Gasbarrini A; Rapaccini GL; Basile U
Scand J Immunol; 2021 Mar; 93(3):e12977. PubMed ID: 32931622
[TBL] [Abstract][Full Text] [Related]
27. Immunopathogenesis and treatment of cytokine storm in COVID-19.
Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
[TBL] [Abstract][Full Text] [Related]
28. Innate immunity, inflammation activation and heat-shock protein in COVID-19 pathogenesis.
Danladi J; Sabir H
J Neuroimmunol; 2021 Sep; 358():577632. PubMed ID: 34186336
[TBL] [Abstract][Full Text] [Related]
29. The cytokine storm-An appropriate, over-reactive response to SARS-CoV-2 or the wrong immune pathway?
Bellgrau D; Modiano JF
Scand J Immunol; 2021 Mar; 93(3):e12979. PubMed ID: 32991014
[No Abstract] [Full Text] [Related]
30. Emerging roles of extracellular vesicles in COVID-19, a double-edged sword?
Xia X; Yuan P; Liu Y; Wang Y; Cao W; Zheng JC
Immunology; 2021 Aug; 163(4):416-430. PubMed ID: 33742451
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial and Amyloidogenic Activity of Peptides. Can Antimicrobial Peptides Be Used against SARS-CoV-2?
Kurpe SR; Grishin SY; Surin AK; Panfilov AV; Slizen MV; Chowdhury SD; Galzitskaya OV
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333996
[TBL] [Abstract][Full Text] [Related]
32. The cytokine storm in COVID-19: Further advances in our understanding the role of specific chemokines involved.
Coperchini F; Chiovato L; Ricci G; Croce L; Magri F; Rotondi M
Cytokine Growth Factor Rev; 2021 Apr; 58():82-91. PubMed ID: 33573850
[TBL] [Abstract][Full Text] [Related]
33. Elevated Interleukin-10 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-Inflammatory Action?
Islam H; Chamberlain TC; Mui AL; Little JP
Front Immunol; 2021; 12():677008. PubMed ID: 34234779
[No Abstract] [Full Text] [Related]
34. Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review.
Roshanravan N; Seif F; Ostadrahimi A; Pouraghaei M; Ghaffari S
Arch Med Res; 2020 Oct; 51(7):608-612. PubMed ID: 32682575
[TBL] [Abstract][Full Text] [Related]
35. The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease.
Pasrija R; Naime M
Int Immunopharmacol; 2021 Jan; 90():107225. PubMed ID: 33302033
[TBL] [Abstract][Full Text] [Related]
36. Can molecular mimicry explain the cytokine storm of SARS-CoV-2?: An in silico approach.
Obando-Pereda G
J Med Virol; 2021 Sep; 93(9):5350-5357. PubMed ID: 33913542
[TBL] [Abstract][Full Text] [Related]
37. Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i).
Pinheiro MM; Fabbri A; Infante M
Immunotherapy; 2021 Jun; 13(9):753-765. PubMed ID: 33906375
[TBL] [Abstract][Full Text] [Related]
38. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.
Olajide OA; Iwuanyanwu VU; Lepiarz-Raba I; Al-Hindawi AA
Inflammation; 2021 Oct; 44(5):1865-1877. PubMed ID: 33860869
[TBL] [Abstract][Full Text] [Related]
39. Des-Arg9 bradykinin and bradykinin potentially trigger cytokine storm in patients with COVID-19.
Alikhani M; Javadi A; Aalikhani M
Iran J Immunol; 2021 Mar; 18(1):93-94. PubMed ID: 33787518
[No Abstract] [Full Text] [Related]
40. Modulating the host immune response to fight against COVID-19: Where are we in 2021?
Hertanto DM; Sutanto H; Wiratama BS; Wungu CDK
Virulence; 2021 Dec; 12(1):1732-1736. PubMed ID: 34224330
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
